BIOVIC-B.ST
Biovica International AB (publ) [BIOVIC-B.ST] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BIOVIC-B.ST Stock Summary
Top 10 Correlated ETFs
BIOVIC-B.ST
Top 10 Correlated Stocks
BIOVIC-B.ST
In the News
BIOVIC-B.ST Financial details
Company Rating
-
Market Cap
209.15M
Income
-122.99M
Revenue
5.98M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
37
Optionable
No
Shortable
Yes
Earnings
18 Jun 2024
P/E
-0.97
Forward P/E
-
PEG
-0.43
P/S
35.75
P/B
1.48
P/C
-
P/FCF
-1.84
Quick Ratio
3.13
Current Ratio
3.72
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.4
EPS next Y
-
EPS next Q
-
EPS this Y
52.04%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
21.19%
Revenue last 5Y
2.4%
Revenue Q/Q
-58.06%
EPS Q/Q
-16.98%
-
-
-
-
SMA20
-
SMA50
-50%
SMA100
-50%
Inst Own
-
Inst Trans
-
ROA
-119%
ROE
-99%
ROC
-1.39%
Gross Margin
121%
Oper. Margin
-2001%
Profit Margin
-2005%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.852-10.36
52W High
-93%
52W Low
-30%
RSI
38
Rel Volume
0.38
Avg Volume
179.97K
Volume
67.67K
Perf Week
6.06%
Perf Month
-30%
Perf Quarter
-64.47%
Perf Half Y
-68.61%
-
-
-
-
Beta
1.209
-
-
Volatility
0.03%, 0.11%
Prev Close
0%
Price
0.7
Change
7.36%
Company Profile
- Volume Average 179.97K
- Market Capitalization 209.15M
- Employee 37
- CEO Mr. Anders Rylander
- Headquarters Uppsala,SE
- IPO Date 2017-03-29
-
Website
https://www.biovica.com 
Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
